461 related articles for article (PubMed ID: 28239825)
1. Upregulated serum sclerostin level in the T2DM patients with femur fracture inhibits the expression of bone formation/remodeling-associated biomarkers via antagonizing Wnt signaling.
Wu Y; Xu SY; Liu SY; Xu L; Deng SY; He YB; Xian SC; Liu YH; Ni GX
Eur Rev Med Pharmacol Sci; 2017 Feb; 21(3):470-478. PubMed ID: 28239825
[TBL] [Abstract][Full Text] [Related]
2. Sclerostin levels associated with inhibition of the Wnt/β-catenin signaling and reduced bone turnover in type 2 diabetes mellitus.
Gaudio A; Privitera F; Battaglia K; Torrisi V; Sidoti MH; Pulvirenti I; Canzonieri E; Tringali G; Fiore CE
J Clin Endocrinol Metab; 2012 Oct; 97(10):3744-50. PubMed ID: 22855334
[TBL] [Abstract][Full Text] [Related]
3. Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus.
van Lierop AH; Hamdy NA; van der Meer RW; Jonker JT; Lamb HJ; Rijzewijk LJ; Diamant M; Romijn JA; Smit JW; Papapoulos SE
Eur J Endocrinol; 2012 Apr; 166(4):711-6. PubMed ID: 22267280
[TBL] [Abstract][Full Text] [Related]
4. Amelioration of bone fragility by pulsed electromagnetic fields in type 2 diabetic KK-Ay mice involving Wnt/β-catenin signaling.
Shao X; Yang Y; Tan Z; Ding Y; Luo E; Jing D; Cai J
Am J Physiol Endocrinol Metab; 2021 May; 320(5):E951-E966. PubMed ID: 33719588
[TBL] [Abstract][Full Text] [Related]
5. Low serum levels of bone turnover markers are associated with the presence and severity of diabetic retinopathy in patients with type 2 diabetes mellitus.
An Y; Liu S; Wang W; Dong H; Zhao W; Ke J; Zhao D
J Diabetes; 2021 Feb; 13(2):111-123. PubMed ID: 32671958
[TBL] [Abstract][Full Text] [Related]
6. Decreased Serum Wnt Antagonist Levels in Patients With Active Acromegaly.
Chen H; Huang H; Wang Y; Zhang Y; Liu M; Lou Y; Zhang Z; Zhu D; Li P
Endocr Pract; 2022 May; 28(5):515-520. PubMed ID: 35123069
[TBL] [Abstract][Full Text] [Related]
7. Association between serum levels of bone turnover markers and bone mineral density in men and women with type 2 diabetes mellitus.
Zhao C; Liu G; Zhang Y; Xu G; Yi X; Liang J; Yang Y; Liang J; Ma C; Ye Y; Yu M; Qu X
J Clin Lab Anal; 2020 Apr; 34(4):e23112. PubMed ID: 31733013
[TBL] [Abstract][Full Text] [Related]
8. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover.
van Lierop AH; Hamdy NA; Hamersma H; van Bezooijen RL; Power J; Loveridge N; Papapoulos SE
J Bone Miner Res; 2011 Dec; 26(12):2804-11. PubMed ID: 21786318
[TBL] [Abstract][Full Text] [Related]
9. 24-hour profile of serum sclerostin and its association with bone biomarkers in men.
Swanson C; Shea SA; Wolfe P; Markwardt S; Cain SW; Munch M; Czeisler CA; Orwoll ES; Buxton OM
Osteoporos Int; 2017 Nov; 28(11):3205-3213. PubMed ID: 28744601
[TBL] [Abstract][Full Text] [Related]
10. Suppressed bone turnover was associated with increased osteoporotic fracture risks in non-obese postmenopausal Chinese women with type 2 diabetes mellitus.
Jiajue R; Jiang Y; Wang O; Li M; Xing X; Cui L; Yin J; Xu L; Xia W
Osteoporos Int; 2014 Aug; 25(8):1999-2005. PubMed ID: 24760246
[TBL] [Abstract][Full Text] [Related]
11. Changes of bone turnover markers after elderly hip fracture surgery.
Li XP; Li XY; Yang MH; Zhu SW; Wu XB; Zhang P
J Bone Miner Metab; 2021 Mar; 39(2):237-244. PubMed ID: 32876727
[TBL] [Abstract][Full Text] [Related]
12. Association between serum ferritin and bone turnover marker levels in type 2 diabetes mellitus patients with non-alcoholic fatty liver disease.
Chen C; Zhao Y; Lv X; Li K; Wang Y; Ma D; Han M; Zan X; Guo X; Liu J
Postgrad Med; 2024 Apr; 136(3):292-301. PubMed ID: 38511546
[TBL] [Abstract][Full Text] [Related]
13. Thalassemic osteopathy: a new marker of bone deposition.
Baldini M; Forti S; Orsatti A; Marcon A; Ulivieri FM; Airaghi L; Zanaboni L; Cappellini MD
Blood Cells Mol Dis; 2014; 52(2-3):91-4. PubMed ID: 24091145
[TBL] [Abstract][Full Text] [Related]
14. Increased levels of Dickkopf-1 are indicative of Wnt/β-catenin downregulation and lower osteoblast signaling in children and adolescents with type 1 diabetes mellitus, contributing to lower bone mineral density.
Tsentidis C; Gourgiotis D; Kossiva L; Marmarinos A; Doulgeraki A; Karavanaki K
Osteoporos Int; 2017 Mar; 28(3):945-953. PubMed ID: 27766367
[TBL] [Abstract][Full Text] [Related]
15. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.
Gifre L; Ruiz-Gaspà S; Monegal A; Nomdedeu B; Filella X; Guañabens N; Peris P
Bone; 2013 Nov; 57(1):272-6. PubMed ID: 23981659
[TBL] [Abstract][Full Text] [Related]
16. Low Bone Turnover Markers in Young and Middle-Aged Male Patients with Type 2 Diabetes Mellitus.
Liu XX; Jiang L; Liu Q; Zhang J; Niu W; Liu J; Zhang Q
J Diabetes Res; 2020; 2020():6191468. PubMed ID: 32851096
[TBL] [Abstract][Full Text] [Related]
17. The relationship between inhibitors of the Wnt signalling pathway (sclerostin and Dickkopf-1) and carotid intima-media thickness in postmenopausal women with type 2 diabetes mellitus.
Gaudio A; Privitera F; Pulvirenti I; Canzonieri E; Rapisarda R; Fiore CE
Diab Vasc Dis Res; 2014 Jan; 11(1):48-52. PubMed ID: 24227537
[TBL] [Abstract][Full Text] [Related]
18. Sclerostin levels and changes in bone metabolism after bariatric surgery.
Muschitz C; Kocijan R; Marterer C; Nia AR; Muschitz GK; Resch H; Pietschmann P
J Clin Endocrinol Metab; 2015 Mar; 100(3):891-901. PubMed ID: 25490275
[TBL] [Abstract][Full Text] [Related]
19. Serum sclerostin levels are decreased in adult patients with different types of osteogenesis imperfecta.
Kocijan R; Muschitz C; Fahrleitner-Pammer A; Amrein K; Pietschmann P; Haschka J; Dinu S; Kapiotis S; Resch H
J Clin Endocrinol Metab; 2014 Feb; 99(2):E311-9. PubMed ID: 24203063
[TBL] [Abstract][Full Text] [Related]
20. Association of Insulin Resistance and β-cell Function With Bone Turnover Biomarkers in Dysglycemia Patients.
Guo H; Wang C; Jiang B; Ge S; Cai J; Zhou Y; Ying R; Zha K; Zhou J; Wang N; Zhu C; Cao C; Zhang L; Gu T; Zhao Y; Lu Y; An Z
Front Endocrinol (Lausanne); 2021; 12():554604. PubMed ID: 33841321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
